• A Company Dedicated to Safe Therapeutic Modulation of Monoamine Neurotransmitter

    Read more

  • Interim Report January – September 2025

    November 21, 2025

    Read the report

Press releases

Older releases

Latest reports

All reports

Calendar

All events

Share

Read more

Initiator Pharma Numbers

  • Expected Number of men affected by Erectile Dysfunction worldwide by 2025 322 million
  • Number of women in the US and Europe suffering from Vulvodynia 27 million
  • Men with Erectile Dysfunction who do not respond to drug therapy 40 %
Initiatorpharma-module-homepage-1-22102021

Initiator Pharma currently has a portfolio of five projects, of which three are in clinical development and two are in preclinical development.

View our Pipeline

CEO letter

In the third quarter of 2025, following our successful capital raise during the summer, Initiator Pharma focused on preparing our planned randomized, placebo-controlled Phase IIa proof-of-concept study in 24 women with vulvodynia – a debilitating condition with no approved therapies and a significant unmet medical need.

Read the full letter
Initiatorpharma-module-homepage-2-22102021

Monoamine transporters is a unique class of proteins that are located just outside the synaptic cleft (peri-synaptically), transporting monoamine transmitter overflow from the synaptic cleft back to the cytoplasm of the pre-synaptic neuron. Our unique monoamine reupdate inhibitors are targeting the monoamine transporters to increase the levels of monoamine transmitters in diseases.

Read more about our technology